The 3 most recent market catalysts affecting $SPYR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 75
Spyre's SPY003 Met Its Primary Endpoint
Spyre announced that SPY003, an anti-IL-23 drug, successfully met its primary endpoint in a Phase 2 trial, demonstrating a statistically significant reduction in RHI score. This is…
Aug 26, 2026
Corporate Catalyst
Bearish
Impact 85
Spyre Therapeutics shares are trading lower after the company announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. The results did not meet the company's internal bar to prioritize advancement of SPY072 in RA.
This headline represents a significant corporate catalyst for Spyre Therapeutics. The failure of SPY072 to meet internal advancement criteria in the RA sub-study is a direct blow t…
Aug 25, 2026
Corporate Catalyst
Bearish
Impact 85
Spyre Therapeutics shares are trading lower after the company announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. The results did not meet the company's internal bar to prioritize advancement of SPY072 in RA.
This headline represents a significant negative corporate catalyst for Spyre Therapeutics. The failure of SPY072 to meet internal efficacy bars in a Phase 2 RA sub-study is a major…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.